RE:News With a prevalence of < 1: 1,000,000, AS will obviously not be the future cash cow fueling any earning growth for PLI. But it is highly strategic both because it touches so many organs that it could turn out in the greatest anti-fibrotic show case in humans that a pharma could dream to boast at regulatory agencies, and precisely because its prevalence is so small that the pivotal clinical trial will most likely ends up small and "fast".
That will not only benefit Prometic, but the cohorts of suffering patients, not only AS ones but all others which share fibrotic organs with AS, which will see acceleration of a drug easing improving or curing their conditions.
Meanwhile, AS offers a second, relatively rapid, opportunity for PLI to obtain a pediatric voucher in the not so distant future. Which could further accelerate 4050 advancement for a larger indication or provide non dilutive cash inflow to finance PLI prodigious pipeline. And my guts tells me it's not gonna be the last...
:-)
FD